地特胰岛素联合瑞格列奈治疗老年2型糖尿病的临床疗效观察(1)
[摘要] 目的 观察地特胰岛素联合瑞格列奈治疗老年2型糖尿病的临床疗效。 方法 选取2016年1月～2017年1月我院收治的老年2型糖尿病患者100例，采用随机数字表法随机分为两组，每组各50例，对照组应用地特胰岛素进行治疗，观察组同时联合瑞格列奈治疗，观察疗程 8 周。观察两组患者治疗前后空腹血糖水平、餐后2 h血糖水平、糖化血红蛋白(HbA1c)的变化情况，并对两组治疗后的临床疗效进行评价。 结果 观察组的临床总有效率显著高于对照组(P<0.05)。观察组患者的FPG、2hPG、HbA1c水平均明显低于对照组，差异具有统计学意义(P<0.05)。观察组的低血糖发生率显著低于对照组(P<0.05)。 结论 地特胰岛素联合瑞格列奈治疗老年2型糖尿病临床疗效确切，安全性好，值得临床广泛推广和应用。
[关键词] 老年2型糖尿病；地特胰岛素；瑞格列奈；低血糖
[中图分类号] R587.1 [文献标识码] B [文章编号] 1673-9701(2017)29-0083-03
Observation of the clinical efficacy of insulin detemir combined with repaglinide in the treatment of senile type 2 diabetes mellitus
LIU Qiang1 LIU Lei1 AN Qingwen2
1.Department of Pharmacy， Dalian Third People’s Hospital， Dalian 116023， China； 2.Clinical Pharmacology， Dalian Third People’s Hospital， Dalian 116023， China
[Abstract] Objective To observe the clinical efficacy of insulin detemir combined with repaglinide in the treatment of senile type 2 diabetes mellitus. Methods A total of 100 patients with senile type 2 diabetes mellitus who were admitted to our hospital from January 2016 to January 2017 were selected. The patients were randomly divided into two groups according to the method of random number table， with 50 patients in each group. The control group was given insulin detemir， and the observation group was given repaglinide. The course of treatment was 8 weeks. The changes of the levels of fasting blood glucose， postprandial 2 h blood glucose and glycosylated hemoglobin(HbA1c) were observed before and after treatment in both groups， and the clinical efficacy of the two groups after treatment was evaluated. Results The total effective rate in the observation group was significantly higher than that in the control group(P<0.05). The levels of FPG， 2hPG and HbA1c in the observation group were significantly lower than those in the control group， and the differences were significant(P<0.05). The incidence rate of hypoglycemia in the observation group was significantly lower than that in the control group(P<0.05). Conclusion The clinical efficacy of insulin detemir combined with repaglinide in the treatment of senile type 2 diabetes mellitus is effective and safe， which is worthy of widespread clinical popularization and application.
[Key words] Senile type 2 diabetes mellitus； Insulin detemir； Repaglinide； Hypoglycemia
老年2型糖尿病是臨床的常见病、多发病，由于其自身生理特点以及病程较长，患者常合并不同程度的并发症，且在治疗过程中易出现较为严重的低血糖等不良反应[1]。目前治疗2型糖尿病的主要药物为胰岛素，其中地特胰岛素属于促进基因重组的新型药物，研究证实其具有控制血糖波动的作用[2]。瑞格列奈是一种新型短效非磺脲类口服胰岛素促分泌剂及餐时血糖调节剂，研究证实其具有加速胰岛素在体内的分泌和吸收，促进血糖的快速降低，并保持在正常水平的作用[3-4]。本研究旨在探讨地特胰岛素、瑞格列奈二者联用治疗老年2型糖尿病的临床疗效，现报道如下。, http://www.100md.com(刘强 刘磊 安庆文)
[关键词] 老年2型糖尿病；地特胰岛素；瑞格列奈；低血糖
[中图分类号] R587.1 [文献标识码] B [文章编号] 1673-9701(2017)29-0083-03
Observation of the clinical efficacy of insulin detemir combined with repaglinide in the treatment of senile type 2 diabetes mellitus
LIU Qiang1 LIU Lei1 AN Qingwen2
1.Department of Pharmacy， Dalian Third People’s Hospital， Dalian 116023， China； 2.Clinical Pharmacology， Dalian Third People’s Hospital， Dalian 116023， China
[Abstract] Objective To observe the clinical efficacy of insulin detemir combined with repaglinide in the treatment of senile type 2 diabetes mellitus. Methods A total of 100 patients with senile type 2 diabetes mellitus who were admitted to our hospital from January 2016 to January 2017 were selected. The patients were randomly divided into two groups according to the method of random number table， with 50 patients in each group. The control group was given insulin detemir， and the observation group was given repaglinide. The course of treatment was 8 weeks. The changes of the levels of fasting blood glucose， postprandial 2 h blood glucose and glycosylated hemoglobin(HbA1c) were observed before and after treatment in both groups， and the clinical efficacy of the two groups after treatment was evaluated. Results The total effective rate in the observation group was significantly higher than that in the control group(P<0.05). The levels of FPG， 2hPG and HbA1c in the observation group were significantly lower than those in the control group， and the differences were significant(P<0.05). The incidence rate of hypoglycemia in the observation group was significantly lower than that in the control group(P<0.05). Conclusion The clinical efficacy of insulin detemir combined with repaglinide in the treatment of senile type 2 diabetes mellitus is effective and safe， which is worthy of widespread clinical popularization and application.
[Key words] Senile type 2 diabetes mellitus； Insulin detemir； Repaglinide； Hypoglycemia
老年2型糖尿病是臨床的常见病、多发病，由于其自身生理特点以及病程较长，患者常合并不同程度的并发症，且在治疗过程中易出现较为严重的低血糖等不良反应[1]。目前治疗2型糖尿病的主要药物为胰岛素，其中地特胰岛素属于促进基因重组的新型药物，研究证实其具有控制血糖波动的作用[2]。瑞格列奈是一种新型短效非磺脲类口服胰岛素促分泌剂及餐时血糖调节剂，研究证实其具有加速胰岛素在体内的分泌和吸收，促进血糖的快速降低，并保持在正常水平的作用[3-4]。本研究旨在探讨地特胰岛素、瑞格列奈二者联用治疗老年2型糖尿病的临床疗效，现报道如下。, http://www.100md.com(刘强 刘磊 安庆文)